Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a double-blind randomized study of oral UCB0599 in early Parkinson's disease
2020-003265-19Phase 2Completed
- Sponsor
- UCB
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing UCB0599 with Placebo (2 arms). Primary endpoint: MDS-UPDRS Parts I-III total score. Started Dec 2020; status: completed.
02
Drugs
minzasolmin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2020-003265-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003265-19.